Free Trial

Bank of New York Mellon Corp Has $54.15 Million Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Henry Schein logo with Medical background

Bank of New York Mellon Corp lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 9.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 790,587 shares of the company's stock after selling 80,334 shares during the period. Bank of New York Mellon Corp owned 0.65% of Henry Schein worth $54,147,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Investment Management Corp VA ADV acquired a new stake in shares of Henry Schein in the fourth quarter worth $32,000. Rakuten Securities Inc. acquired a new stake in shares of Henry Schein in the first quarter worth $34,000. UMB Bank n.a. grew its stake in shares of Henry Schein by 23.2% in the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after acquiring an additional 201 shares during the last quarter. Menard Financial Group LLC acquired a new stake in shares of Henry Schein in the fourth quarter worth $92,000. Finally, Canada Post Corp Registered Pension Plan acquired a new stake in shares of Henry Schein in the fourth quarter worth $95,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Stock Down 1.5%

Shares of NASDAQ HSIC opened at $73.42 on Friday. The stock has a market cap of $8.94 billion, a PE ratio of 22.94, a PEG ratio of 2.37 and a beta of 0.87. The business has a fifty day moving average of $71.56 and a two-hundred day moving average of $71.33. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.75 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a return on equity of 14.87% and a net margin of 3.21%. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. During the same period in the previous year, the business posted $1.10 earnings per share. The firm's revenue for the quarter was down .1% compared to the same quarter last year. As a group, equities research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HSIC shares. Piper Sandler lowered their price objective on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Evercore ISI raised their target price on Henry Schein from $72.00 to $78.00 and gave the stock an "in-line" rating in a research report on Wednesday. Barrington Research reduced their target price on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their target price on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Wall Street Zen cut Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $79.70.

Get Our Latest Research Report on HSIC

Henry Schein Profile

(Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Stories

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Henry Schein Right Now?

Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines